Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05977400 · ClinicalTrials.gov registry record · Phase 3
NICU Antibiotics and Outcomes (NANO) Follow-up Study
A Phase 3 study, sponsored by Sharp HealthCare.
- Not yet
- Registry status
- Phase 3
- Development phase
- 802
- Enrollment target
NCT05977400: Clinical Trial Phase 3 study, sponsored by Sharp HealthCare.
NCT05977400 is a Phase 3 study that has not yet begun recruiting, run by Sharp HealthCare. The registered enrollment target is 802 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05977400, a Phase 3 study, has not yet begun recruiting, sponsored by Sharp HealthCare.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 802 participants
- Enrollment target
Study Summary
The NANO follow-up study is designed to determine whether a simple, cost-effective intervention- withholding antibiotics at birth- reduces clinically relevant outcomes such as behavioral and neurological impairment at 2 years of age. This study will be the largest study evaluating the effects of early antibiotics in children with comprehensive measures of neurodevelopment linked to genomic variants and microbiota interactions.
Interventions
- DRUG Placebo
- DRUG Gentamicin
- DRUG Ampicillin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 802 participants |
| Start Date | 2024-04 |
| Est. Completion | 2029-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05977400
The ClinicalTrials.gov registry entry for NCT05977400 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 802 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sharp HealthCare, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05977400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05977400 about?
NCT05977400 is a clinical study titled "NICU Antibiotics and Outcomes (NANO) Follow-up Study". The NANO follow-up study is designed to determine whether a simple, cost-effective intervention- withholding antibiotics at birth- reduces clinically relevant outcomes such as behavioral and neurological impairment at 2 years of age. This study will be the largest study evaluating the effects of ear...
What is the current status of trial NCT05977400?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 802 participants. The study started on 2024-04. Estimated completion is 2029-03.
What interventions are being tested in trial NCT05977400?
The interventions under investigation include: Placebo (DRUG), Gentamicin (DRUG), Ampicillin (DRUG).
Who is sponsoring clinical trial NCT05977400?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.